Navigation Links
Sanofi-aventis Announces Good First-quarter 2009 Performance
Date:4/29/2009

2,178 million, up 15.7% (8.7% at constant exchange rate). The ratio of adjusted net income excluding selected items(1) to net sales improved by 3.5 points to 30.6%.

Adjusted earnings per share (EPS) excluding selected items was euro 1.67. This represents growth of 16.8% versus the 2008 first-quarter figure of euro 1.43, or 9.8% growth at constant exchange rates.

Selected Items

Selected items represented a net loss of euro 18 million for the quarter, compared with a net loss of euro 20 million for the first quarter of 2008. The 2009 first-quarter figure comprises:

  • euro 8 million of restructuring costs arising on adaptation measures initiated in 2008 in Europe;
  • euro 20 million of impairment losses arising from the decision to halt the development of TroVax(R);
  • net of the euro 10 million tax effect on the selected items described above.

Adjustments in the consolidated financial statements to reflect the application of purchase accounting to acquisitions, primarily that of Aventis

Research and Development

Review of the R&D portfolio

We have just completed a comprehensive and rigorous review of our R&D portfolio, the first critical phase in the transformation of our Research & Development effort. This was an objective exercise, performed by a mix of in-house teams and external consultants. Our project reassessment process looked not only at scientific and medical criteria (in particular, the degree of innovation) but also at commercial, regulatory and market access criteria (such as the extent of patient needs, the expected value of each project, and the commercial risk). This review has enabled us to refocus our portfolio on the most promising projects and to reallocate resources
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Sanofi-Aventis and Roche/Chugais Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
2. Sanofi-aventis Affirms Its Commitment to Partnering with Local Communities to Improve Hispanic and African American Health
3. Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States
4. Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
5. Sanofi-aventis Partners with the Hispanic Community in Miami to Increase Health Awareness, Access to Resources and Help Improve Patient Care
6. Sanofi-aventis Partners with the Hispanic Community in San Antonio to Increase Health Awareness, Access to Resources and Help Improve Patient Care
7. Sanofi-aventis Delivers 2008 Results Above Guidance
8. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
9. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
10. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
11. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... 21, 2014 The Laboratory Testing Services ... manufacturers perform tests on items ranging from consumer and ... society, pressure on operators to ensure the safety and ... greater number of government safety regulations and consumer lawsuits ... to sale. Although revenue briefly dipped in 2009 as ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... enabled more generic drugs to inundate the market, thereby ... Pharmaceutical Manufacturing industry. According to data from Industry ... has cost the industry $1.8 and $2.5 billion in ... brand-name drugs losing patent exclusivity, which has hampered revenue ...
(Date:9/21/2014)... 22, 2014 The asthma market ... as it has become saturated with relatively efficacious ... corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), ... increasing generic competition. However, the launch of seven ... ICS/LABA therapies delivered by the next-generation inhalers will ...
(Date:9/21/2014)... The Illinois Joining Forces Behavioral Health ... symposium ( tinyurl.com/ILBHC14 ) focused on improving care ... by the VNA Foundation, Thresholds, Illinois Department of ... & Disability Advocates, the symposium will be held ... Springfield, IL. The symposium features keynote speakers ...
(Date:9/21/2014)... September 21, 2014 Hundreds of ... forward in Pennsylvania’s Philadelphia Court of Common Pleas, ... the proceeding’s next monthly meeting has been scheduled ... 100300296) , “Our Firm is representing a number ... this litigation. We are pleased with its continued ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4
... say combining a 6 percent salicylic acid gel with ... for plaque psoriasis, an inflammatory skin condition characterized by ... study 30 adults with plaque-type psoriasis were observed for ... acid gel plus 0.1 percent tacrolimus ointment or 6 ...
... According to findings of a recent study researchers say ... kidney stone formation.//Researchers believe larger body size causes increased ... higher risk for calcium-containing kidney stones. ,The association ... gain, body mass index, and waist circumference was studied ...
... past have shown conflicting results over whether hormone replacement ... A recent study however examines the pros and cons ... used combined HRT therapy for five years. All the ... participants had menopausal symptoms, while others did not.Results showed ...
... intake during pregnancy may increase the likelihood of eczema ... according to a recent study.// ,2,000 women were ... the development of asthma and eczema in children. The ... women. The participants were required to fill out questionnaires ...
... results suggest people who carry a gene that produces ... a small increased risk for stroke.// ,Researchers reviewed ... was found that previous study results were observational in ... out confounding factors by looking at data on the ...
... Year has brought with it a new lease of life ... //patients the uphill struggle doesn’t stop with finding a matching ... Research has shown that despite all high tech matching done ... phenomenon. Transplant surgeon Ignazio Marino, M.D., of Thomas Jefferson University ...
Cached Medicine News:
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... Sept. 19, 2014  Pressure BioSciences, Inc. (OTCQB: ... has received and approved all parts required to ... has begun to manufacture the new PCT-based instrument ... be ready for shipment by mid-October and that ... at a rate of about one per week ...
(Date:9/19/2014)...  Over 200 runners participated in the fifth annual ... Oncology Institute (ROI), hosted by Radiation Business Solutions. This year ... San Francisco.  "Donations are still coming ... Business Solutions, "but at this point, through registrations ... the ROI this year. This surpasses last year,s record ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced ... approval for Pixuvri™ (pixantrone dimaleate) for the treatment ... aggressive non-Hodgkin,s lymphoma ("NHL") was validated and accepted ... Validation indicates that the application is complete and ...
... 2010 Hanger Orthopedic Group, Inc. (NYSE: ... (the "Offer") for any and all of its outstanding 10 ... expired at 8:00 a.m., New York City time, on November 17, ... $172,443,000 aggregate principal amount of Notes had been validly tendered ...
Cached Medicine Technology:The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 3Hanger Orthopedic Group, Inc. Announces Expiration of Offer to Purchase Outstanding 10 1/4% Senior Notes Due 2014 2Hanger Orthopedic Group, Inc. Announces Expiration of Offer to Purchase Outstanding 10 1/4% Senior Notes Due 2014 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: